Skip to content

Girls OnGuard: HPV Vaccination Uptake Among African American Adolescent Females

Overcoming Barriers to Vaccination With GARDASIL in Underserved Girls and Adolescents

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00813319
Acronym
Girls OnGuard
Enrollment
216
Registered
2008-12-23
Start date
2009-10-31
Completion date
2014-03-31
Last updated
2014-08-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vaccination

Keywords

GARDASIL, HPV, Vaccination

Brief summary

African American adolescent females seeking treatment for STIs are an underserved population at increased risk for HPV infection. While GARDASIL is an effective preventive vaccine, vaccination rates are low. Given the risk for HPV infection among this subgroup and the negative health effects associated with HPV, enhancing uptake of GARDASIL is necessary. The goal of this project is to promote GARDASIL vaccination through the development of a new multi-component, culturally-appropriate, interactive DVD. We propose to recruit 280 unmarried African American adolescent females, 13-18 years of age, from participating clinic sites in Atlanta, Georgia. While seeking clinical services, adolescents will be contacted and invited to participate in the proposed study. Eligible adolescents will be required to provide written assent/consent prior to participation. Adolescents who are eligible and willing to participate in the project will complete a short survey on a laptop computer. The survey is designed to assess adolescents' risk taking and preventive behaviors. After they complete the survey, adolescents will be assigned at random to one of two groups. In one group, adolescents will watch a short (10 min), interactive DVD designed to promote HPV awareness and initial GARDASIL vaccination and receive a keepsake to help them remember to return to the clinic for their second and third vaccine doses. In the second group, adolescents will watch an equally short (10 min) DVD on healthy lifestyles and behaviors. All adolescents are eligible to receive the GARDASIL vaccine at participating study clinics as part of their routine standard of care. With the help of clinic staff, participant medical records will be reviewed over a 7 month period to assess vaccination rates. Vaccination rates from adolescents who received the interactive HPV/GARDASIL awareness DVD will be compared to the group of adolescents who received the healthy lifestyles DVD. It is hypothesized that study participants receiving the interactive DVD intervention that promotes HPV awareness will have higher vaccination rates over time.

Interventions

BEHAVIORALGirls OnGuard

Using the Information-Motivation-Behavioral Skills Model (IMB) as a framework, Girls OnGuard is an interactive,culturally-appropriate, computer-delivered program design to enhance initial uptake of GARDASIL by addressing three major components: (1) information about GARDASIL; (2) motivation to obtain GARDASIL vaccination; and (3) behavioral skills to enhance self-efficacy of obtaining GARDASIL vaccination.

Sponsors

Merck Sharp & Dohme LLC
CollaboratorINDUSTRY
Emory University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
13 Years to 18 Years
Healthy volunteers
Yes

Inclusion criteria

* African American * Female * Age 13-18 years * Seeking reproductive/STI services at participating clinic * Ability to give written informed consent or assent

Exclusion criteria

* Pregnant * Married * Already received the HPV vaccine

Design outcomes

Primary

MeasureTime frameDescription
GARDASIL Vaccination Uptake and Compliance With Second and Third Dosesmeasured at 7 months post-randomizationNumber of participants who received at least 1 dose, 2 doses, 3 doses
Total Doses Received of HPV Vaccinemeasured at 7-months post randomizationAs an additional primary outcome, we assessed the total number of vaccine doses received

Secondary

MeasureTime frameDescription
STD Incidence7 months post randomizationNumber of participants who tested positive for any STD 7 months post randomization, information was gathered via medical chart abstraction

Countries

United States

Participant flow

Participants by arm

ArmCount
1 - Girls OnGuard/HPV Awareness
Adolescents will watch a short (10 min), interactive DVD designed to promote HPV awareness and initial GARDASIL vaccination and receive a keepsake to help them remember to return to the clinic for their second and third vaccine doses. Girls OnGuard: Using the Information-Motivation-Behavioral Skills Model (IMB) as a framework, Girls OnGuard is an interactive,culturally-appropriate, computer-delivered program design to enhance initial uptake of GARDASIL by addressing three major components: (1) information about GARDASIL; (2) motivation to obtain GARDASIL vaccination; and (3) behavioral skills to enhance self-efficacy of obtaining GARDASIL vaccination.
108
2 - General Health Promotion
Adolescents will watch an equally short (10 min) DVD on healthy lifestyles and behaviors. HPV awareness and vaccination will not be addressed.
108
Total216

Baseline characteristics

Characteristic1 - Girls OnGuard/HPV Awareness2 - General Health PromotionTotal
Age, Categorical
<=18 years
108 Participants108 Participants216 Participants
Age, Categorical
>=65 years
0 Participants0 Participants0 Participants
Age, Categorical
Between 18 and 65 years
0 Participants0 Participants0 Participants
Age, Continuous16.68 Years
STANDARD_DEVIATION 1.44
16.26 Years
STANDARD_DEVIATION 1.54
16.47 Years
STANDARD_DEVIATION 1.5
Region of Enrollment
United States
108 participants108 participants216 participants
Sex: Female, Male
Female
108 Participants108 Participants216 Participants
Sex: Female, Male
Male
0 Participants0 Participants0 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
— / —— / —
other
Total, other adverse events
0 / 1080 / 108
serious
Total, serious adverse events
0 / 1080 / 108

Outcome results

Primary

GARDASIL Vaccination Uptake and Compliance With Second and Third Doses

Number of participants who received at least 1 dose, 2 doses, 3 doses

Time frame: measured at 7 months post-randomization

ArmMeasureGroupValue (NUMBER)
1 - Girls OnGuard/HPV AwarenessGARDASIL Vaccination Uptake and Compliance With Second and Third DosesNumber of participants who received at least 1 dos12 participants
1 - Girls OnGuard/HPV AwarenessGARDASIL Vaccination Uptake and Compliance With Second and Third DosesNumber of participants who received 2 doses8 participants
1 - Girls OnGuard/HPV AwarenessGARDASIL Vaccination Uptake and Compliance With Second and Third DosesNumber of participants who received 3 doses6 participants
2 - General Health PromotionGARDASIL Vaccination Uptake and Compliance With Second and Third DosesNumber of participants who received at least 1 dos12 participants
2 - General Health PromotionGARDASIL Vaccination Uptake and Compliance With Second and Third DosesNumber of participants who received 2 doses3 participants
2 - General Health PromotionGARDASIL Vaccination Uptake and Compliance With Second and Third DosesNumber of participants who received 3 doses2 participants
Comparison: This comparison is for participants in the Girls OnGuard/HPV Awareness condition compared to the General Health Promotion conditionp-value: >0.05Chi-squared
Primary

Total Doses Received of HPV Vaccine

As an additional primary outcome, we assessed the total number of vaccine doses received

Time frame: measured at 7-months post randomization

ArmMeasureValue (NUMBER)
1 - Girls OnGuard/HPV AwarenessTotal Doses Received of HPV Vaccine26 Doses
2 - General Health PromotionTotal Doses Received of HPV Vaccine17 Doses
Comparison: This comparison is for total doses received (26 in Girls OnGuard/HPV Awareness condition compared to 17 in General Health Promotion condition)p-value: =0.12Chi-squared
Secondary

STD Incidence

Number of participants who tested positive for any STD 7 months post randomization, information was gathered via medical chart abstraction

Time frame: 7 months post randomization

ArmMeasureValue (NUMBER)
1 - Girls OnGuard/HPV AwarenessSTD Incidence35 participants
2 - General Health PromotionSTD Incidence32 participants
p-value: =0.52Chi-squared

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026